BioNTech लाइव चार्ट

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

नवीनतम समाचार

और दिखाएं
Frances Wang 2025 मई 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 मई 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 मई 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds
Tommy Yap 2025 मई 08, 16:00

Morning Note: Dollar Climbs on Trade Winds; BTC Soars; ECB's Dovish Tone

Morning Note Forex Cryptocurrencies
Frances Wang 2025 मई 07, 16:00

Stock Market Today: Dow Jones Up, Nvidia stock fluctuates, Nasdaq Rises

Stocks Indices NVDA
Tommy Yap 2025 मई 07, 16:00

Morning Note: BoE Rate Cut?, US Jobs, Toyota Earnings Today

Morning Note USD GBP
Frances Wang 2025 मई 06, 16:00

Trending forex pairs: EUR/USD Fluctuates, USD/TWD Drops, AUD/JPY Rises

Forex
Tommy Yap 2025 मई 06, 16:00

Morning Note: Fed Rate Decision Awaited; Uber's Report Looms; Oil Recovers Ground

Morning Note Fed Oil USD

जानकारी

स्प्रेड

0.8174

स्प्रेड (%)

0.8839 %

लीवरेज

1:10

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

13:31 - 19:59

मंगवार

13:31-19:59

बुधवार

13:31-19:59

गुरुवार

13:31-19:59

शुक्रवार

13:31-19:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

25226842112

बकाया शेयर

240392992

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

2022-06-17

पूर्व-लाभांश तिथि

2022-06-02

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-3.14

इस उपकरण के बारे में अधिक जानें

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें
view_all_instruments

latest_education_articles

और दिखाएं
Trustpilot